在患有慢性阻塞性肺部疾病的患者中使用 gabapentinoid 相关的严重恶化的风险:基于人口的队列研究
Omotayo Olaoye1,2, Sophie Dell'Aniello2, Pierre Ernst1,2,3
1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
COPD
|July 23, 2025
概括
使用 gabapentinoid 增加了慢性阻塞性肺病 (COPD) 患者严重恶化的风险. 这种风险在和神经病痛等症状中是一致的.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 临床药理学 临床药理学
- 流行病学 流行病学
背景情况:
- 关于长期阻塞性肺病 (COPD) 患者中 gabapentinoids 的呼吸风险的证据有限.
- 加巴类药物通常用于治疗疼痛和神经疾病,通常与COPD同时发生.
研究的目的:
- 评估 gabapentinoid 使用与严重的 COPD 恶化之间的关联.
- 为了研究这种风险在不同的适用于 gabapentinoid 处方.
主要方法:
- 一个使用英国初级保健数据 (1993-2021) 的新用户队列设计.
- 时间条件倾向得分匹配 (1:1) 的 gabapentinoid 用户与非用户.
- 考克斯的比例危险模型分析了严重恶化的风险.
主要成果:
- gabapentinoid的使用与严重COPD恶化的风险增加了43% (HR 1.43; 95% CI: 1.35-1.52).
- 在 (HR 1.39),神经病痛 (HR 1.43) 和其他慢性疼痛 (HR 1.45) 症候群中观察到风险增加.
结论:
- 开始服用 gabapentinoid 与严重COPD恶化的风险较高有关.
- 临床医生在给COPD患者开 gabapentinoids 处方时应考虑这种增加的风险,不论其适用情况如何.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
315
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
315
01:20COPD: Pathogenesis and Clinical Features
529
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
529
01:22Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
280
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
280
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
4.3K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
4.3K
01:30Acute Respiratory Failure-III
325
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
325